Search alternatives:
teer decrease » greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
13841
Image_3_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13842
Presentation_1_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13843
Image_12_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13844
Image_10_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13845
Presentation_3_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13846
Table_4_Global burden of lower respiratory infections during the last three decades.DOC
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13847
Image_2_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13848
Image_4_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13849
Image_6_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13850
Image_7_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13851
Image_13_Global burden of lower respiratory infections during the last three decades.PDF
Published 2023“…The global age-standardized incidence and death rates for LRIs were 6,295 (5,887.4–6,737.3) and 34.3 (31.1–37.9) per 100,000 in 2019, which represents a 23.9% (22.5–25.4) and 48.5% (42.9–54.0) decrease, respectively since 1990. …”
-
13852
Table1_Meta-Analysis Approach to Measure the Effect of Integrated Nutrient Management on Crop Performance, Microbial Activity, and Carbon Stocks in Indian Soils.docx
Published 2021“…<p>Cereal crop production gains under conventional agricultural systems in India have been declining in recent years because of inadequate management practices, creating a considerable concern. These activities were shown to deplete soil organic matter stocks, resulting in a decrease in microbial activity and soil organic carbon (SOC) content. …”
-
13853
Table_2_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.xlsx
Published 2023“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
-
13854
NTS_QECH
Published 2022“…Estimated minimum incidence of iNTS disease decreased from 21/100,000 per year in 2011 to 7/100,000 per year in 2019. …”
-
13855
Table_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx
Published 2023“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
-
13856
Table_3_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.xlsx
Published 2023“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
-
13857
Table_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx
Published 2023“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
-
13858
Increased CN inhibition leads to reduced STO frequency and to more CSpk frequency.
Published 2025“…<p>(A) After Plasticity difference for SSpks is significant across coupled cases for the Upbound zone (t = 4.51, p < 0.001; two-sample Student’s t-test; n = 100) and for coupled case across zones (t = -5.36, p < 0.001; two-sample Student’s t-test; n = 100). …”
-
13859
DataSheet_1_Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.docx
Published 2023“…Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. …”
-
13860
Table1_Changes in the global burden of foreign body aspiration among under-5 children from 1990 to 2019.xls
Published 2023“…Many European countries (such as Italy, Netherlands, Iceland, etc.) showed a high incidence rate, but did not cause a large disease burden (DALYs all less than 200 per 100,000). …”